Breast Cancer, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 37-1 - November 25, 2022
Editor: Harold J. Burstein
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 1 8 5 - 6
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 1 8 6 - 3

In this issue of Hematology/Oncology Clinics, guest editor Dr. Harold J. Burstein brings his considerable expertise to Breast Cancer. Top experts provide a comprehensive update on… Read more

Breast Cancer, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

In this issue of Hematology/Oncology Clinics, guest editor Dr. Harold J. Burstein brings his considerable expertise to Breast Cancer. Top experts provide a comprehensive update on multidisciplinary management of early- and late-stage breast cancer, including key topics such as global perspectives on the epidemiology and treatment of breast cancer; breast cancer pathology in the era of genomics; optimizing radiation therapy after breast conserving surgery; and more.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
Disparities in Breast Cancer Outcomes and How to Resolve Them
Key points
Breast cancer outcomes
Defining the disparities
Differences in stage at diagnosis
Molecular subtypes by race
Survival and outcomes
Incidence and mortality
Reasons for the disparities
Energy imbalance
Birthing habits
Other risk factors for breast cancer
Disparities in screening and diagnosis
Disparities in treatment
The solution: bringing about health equity
Testing for Inherited Susceptibility to Breast Cancer
Key points
Introduction
Rare, high-penetrance variants
Rare, moderate penetrance variants
Common variation and breast cancer risk
Introduction of genetic testing for breast cancer susceptibility
Challenges to the standard model
Considerations regarding universal testing
Summary
Clinics care points
Breast Cancer Pathology in the Era of Genomics
Key points
Introduction
Germline testing
Tumor classification
Adenoid cystic carcinoma
Secretory carcinoma
Tall-cell carcinoma with reversed polarity
Adenomyoepithelioma/malignant adenomyoepithelioma
Prognostic and predictive testing
Ki67
Tumor-infiltrating lymphocytes
Treatment decisions
Immune checkpoint inhibitors and PD-L1 testing
ESR1 mutations
HER2 overexpression, amplification, and mutation
PIK3CA mutations for PI3K inhibitor treatment
Circulating tumor DNA
The utility of genomic analysis in resolving diagnostic dilemmas
Summary
Surgical Management of the Axilla for Breast Cancer
Key points
Background
Discussion
Summary
Clinics care points
Role of Ovarian Suppression in Early Premenopausal Breast Cancer
Key points
History of ovarian suppression
Indirect information relevant to ovarian suppression
21st century randomized trials testing adjuvant ovarian suppression
Ovarian suppression to reduce risk of premature ovarian failure
Can ovarian suppression replace adjuvant chemotherapy in intermediate risk endocrine-responsive premenopausal early breast cancer?
Summary: role of ovarian suppression in early premenopausal breast cancer
Clinics care points
Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
Key points
Introduction
Prognostic factors and assessing risk of recurrence
Adjuvant endocrine therapy in postmenopausal hormone receptor-positive early breast cancer
Adjuvant chemotherapy in postmenopausal hormone receptor-positive early breast cancer
Additional adjuvant systemic therapies in higher-risk hormone receptor-positive early breast cancer
Future directions for adjuvant systemic therapies in hormone receptor-positive early breast cancer
Summary
Clinics care points
Disclosure
Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
Key points
Introduction
Neoadjuvant therapy for early-stage disease
Adjuvant therapy for early-stage disease
De-escalation of therapy in early-stage disease
First-line therapy for metastatic disease
Options in the second line: a fast-moving target
Third-line+ therapy and future directions
Cardiac monitoring considerations
Summary
Disclosure
Biology and Treatment of HER2-Low Breast Cancer
Key points
Introduction
Clinical relevance
Therapeutic options
Discussion
Summary
Clinics care points
Disclosure
Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer
Key points
Introduction
Discussion
Summary
Clinics care points
Disclosure
Funding
Current and Emerging Role of Antibody–Drug Conjugates in HER2-Negative Breast Cancer
Key points
Antibody–drug conjugates: basic structure
Targeting Trop-2
Targeting HER2 (in HER2-low breast cancers)
Targeting LIV1
Targeting HER3-Patritumab deruxtecan (HER-DXd)
Combination therapy
Early breast cancer
Future directions
Clinics care points
The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Key points
Introduction
Initial clinical evidence of the ESR1 mutation as a mechanism of endocrine resistance emerging under the pressure of endocrine treatment
Preclinical characteristics of the ESR1 ligand-binding domain mutations
Studying ESR1 mutations using liquid biopsy
Retrospective circulating tumor DNA analysis of ESR1 mutation and response to endocrine therapy
Clinical use of the ESR1 ligand-binding domain mutations as a therapeutic target
Circulating tumor DNA ESR1 mutation monitoring for therapy decisions
Future perspectives
Multidisciplinary Management of Brain Metastasis from Breast Cancer
Key points
Introduction
Blood–brain barrier, brain microenvironment, and blood tumor barrier
Diagnosis
Therapeutic options
Ongoing studies
Summary
Clinics care points
Systemic Therapy for Hereditary Breast Cancers
Key points
Introduction
Summary
Clinics care points
Evidence-Based Guidance for Breast Cancer Survivorship
Key points
Introduction to breast cancer survivorship
Management of symptoms related to cancer-directed therapy
Mental health concerns
Health and wellness promotion
Financial toxicity
Second cancer screening
Surveillance for breast cancer recurrence
Reproductive concerns
Cardiac/other health concerns
Osteoporosis
Disparities in survivorship
Clinics care points

Life sciences

Physical sciences & Engineering

Social sciences & Humanities

Health

Breast Cancer, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Harold J. Burstein